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H I G H L I G H T S
• Frontotemporal dementia is the second prevalent dementia after Alzheimer's disease.
• GRN mutations leading to PGRN deficiency are linked to frontotemporal dementia.
• PGRN deficiency causes lysosome defects, neurodegeneration, and neuroinflammation.
• Efforts to raise PGRN levels are a therapeutic strategy for frontotemporal dementia.
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A B S T R A C T
Frontotemporal degeneration (FTD) is a complex disease presenting as a spectrum of clinical disorders with
progressive degeneration of frontal and temporal brain cortices and extensive neuroinflammation that result in
personality and behavior changes, and eventually, death. There are currently no effective therapies for FTD.
While 60–70% of FTD patients are sporadic cases, the other 30–40% are heritable (familial) cases linked to
mutations in several known genes. We focus here on FTD caused by mutations in the GRN gene, which encodes a
secreted protein, progranulin (PGRN), that has diverse roles in regulating cell survival, immune responses, and
autophagy and lysosome function in the brain. FTD-linked mutations in GRN reduce brain PGRN levels that lead
to autophagy and lysosome dysfunction, TDP43 accumulation, excessive microglial activation, astrogliosis, and
neuron death through still poorly understood mechanisms. PGRN insufficiency has also been linked to
Alzheimer's disease (AD), and so the development of therapeutics for GRN-linked FTD that restore PGRN levels
and function may have broader application for other neurodegenerative diseases. This review focuses on a
strategy to increase PGRN to functional, healthy levels in the brain by identifying novel genetic and chemical
modulators of neuronal PGRN levels.
1. Introduction
Frontotemporal dementia (FTD) is the most common age-related
dementia in people under 60 years of age (Rabinovici and Miller, 2010;
Rademakers et al., 2012; Riedl et al., 2014; Greaves and Rohrer, 2019).
The clinical presentation of FTD is distinct from Alzheimer's Disease
(AD), the most common age-related dementia, in that there is a major
impairment of executive functioning in FTD rather than an impairment
of memory functions as in AD. At onset, FTD patients can show changes
in personality and social conduct, exhibited by social disinhibition and
distractibility. Patients normally show lapses in judgment, loss of in-
sight, and cognitive deficits in attention, abstraction, planning, and
problem solving and deficits in both expressive and receptive language.
The brains of FTD patients show loss of neurons in the frontal and
temporal lobes. Spindle neurons, important for social behavior, are
especially vulnerable (Seeley et al., 2006, 2007). The FTD brain can be
classified by abnormal deposits of TAR DNA-binding protein 43
(TDP43) and tau. The most prevalent genetic cause of FTD is an ab-
normal hexanucleotide repeat expansion (HNE) in C9ORF72 which is
also associated with TDP43 pathology and comprises about 25% of
familial FTD cases (Van Langenhove et al., 2012). The other frequent
genetic causes of FTD are due to mutations in the microtubule asso-
ciated protein tau (MAPT) gene that encodes tau (5–20% of familial
cases) and result in abnormal tau deposits, or the GRN gene that
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encodes the progranulin (PGRN) protein (5–20% of familial cases) and
result in PGRN insufficiency, and TDP43 pathology (Rademakers et al.,
2012; Ghidoni et al., 2012; Baker et al., 2006; Cruts et al., 2006). PGRN
has been shown to reduce TDP43 phosphorylation and pathology, so
PGRN insufficiency may exacerbate TDP43 pathology in FTD (Beel
et al., 2018; Chang et al., 2017; Fujita et al., 2018; Wils et al., 2012; Yin
et al., 2010a, 2010b). The remaining familial FTD cases are linked to
less frequent mutations in a handful of genes, including valosin-con-
taining protein (VCP; ~1%), sequestosome 1 (SQSTM1; < 1%), ubi-
quilin 2 (UBQLN2; < 1%), optineurin (OPTN;<1%), coiled-coil-helix-
coiled-coil-helix domain containing 10 (CHCHD10; < 1%), TANK
binding kinase 1 (TBK1; 1%–3%), charged multivesicular body protein
2B (CHMP2B; < 1%), and dynactin 1 (DCTN1; < 1%). We will focus
this review on GRN-linked FTD (Ferrari et al., 2019; Deleon and Miller,
2018). Interestingly, a recent meta-analysis suggests that there may be
gender differences in FTD, where there was a higher prevalence of GRN
mutations in female FTD cases (Curtis et al., 2017). There were no sex
differences observed for C9ORF72-related or MAPT-related FTD.
PGRN insufficiency may have a broader role in FTD beyond those
patients with mutations in the GRN gene. A subset of FTD cases are
linked to mutations in the MAPT gene, which encodes the protein tau,
and are considered tauopathies as they result in the aggregation of
phosphorylated tau (p-tau) forms that drive neurodegeneration (Fujita
et al., 2018; Gasparini et al., 2007). Interestingly, PGRN levels can
modulate the extent of the tauopathy: Hosokawa et al. (2015, 2017,
2018) showed that a transgenic mouse model of FTD expressing P301L
tau (MAPT P301L) exhibited increased p-tau, neuropathology and
cognitive deficits and that lowering PGRN levels in brain further ex-
acerbated the tauopathy by augmenting the already increased levels of
p-tau in brain (Hosokawa et al., 2015, 2018). Similarly, when the levels
of a mutant form of tau (P301L tau) associated with increased risk of
FTD were increased in the brains of Grn−/− mice by AAV injection,
there was greatly enhanced expression of p-tau compared to similar
AAV injection into the brains of control mice (Takahashi et al., 2017).
This suggests that PGRN deficiency results in increased expression of a
highly pathogenic forms of tau believed to cause neurodegeneration in
FTD.
PGRN insufficiency has also been linked to AD, a tauopathy that also
presents with TDP43 pathology; 50% of AD patients have TDP43 pa-
thology (Josephs et al., 2014; Wilson et al., 2011). A SNP (rs5848) in
the GRN gene that leads to reduced PGRN levels is linked to increased
risk of AD (Chen et al., 2015; Hsiung et al., 2011; Kamalainen et al.,
2013; Perry et al., 2013; Xu et al., 2016). Reduced PGRN levels ex-
acerbate pathologies in AD mouse models, including impaired micro-
glial function and increased toxic accumulation of amyloid beta and tau
proteins (Hosokawa et al., 2015, 2017, 2018; Minami et al., 2014;
Pereson et al., 2009). Genetically increasing the levels of PGRN in
mouse models of AD suppresses neuroinflammatory-, pathological-, and
cognitive-based disease phenotypes (Hosokawa et al., 2015; Minami
et al., 2014; Pereson et al., 2009).
In the brain, PGRN is expressed primarily by neurons and microglia,
is involved in neuronal survival, neurite outgrowth, and synaptogen-
esis, and is a key regulator of neuroinflammation consistent with its
neuroprotective role in models of FTD and AD (Ahmed et al., 2007;
Cenik et al., 2012; Chitramuthu et al., 2010; Gass et al., 2012; Petkau
and Leavitt, 2014; Petkau et al., 2012; Petoukhov et al., 2013). Little is
known about how PGRN deficiency leads to neurodegeneration in FTD
and AD. Complete loss of PGRN in the brain causes neuronal ceroid
lipofuscinosis, a lysosomal storage disorder, characterized by severe
lysosome dysfunction, and the abnormal accumulation of lipofuscin, a
lipid-rich lysosome degradation residue associated with cell senescence,
aging, and neurodegenerative diseases (Gotzl et al., 2014; Smith et al.,
2012). Haploinsufficiency of PGRN in mouse models of FTD causes
lysosomal defects leading to neurodegeneration and social behavior
dysfunction. This suggests a key role for PGRN in lysosome function
(Ahmed et al., 2010; Evers et al., 2017; Tanaka et al.; Tanaka et al.,
2013a, 2013b, 2014, 2017; Ward, 2017).
PGRN has also been suggested to regulate autophagy, a key cellular
pathway directly linked to lysosomes and involved in the clearance of
misfolded disease-causing proteins such as p-tau and TDP43. PGRN
deficiency leads to dysregulated autophagy and the subsequent accu-
mulation of toxic forms of TDP43 in neurons (Beel et al., 2018; Chang
et al., 2017). Increasing PGRN levels reduced insoluble TDP43 levels in
vitro (Beel et al., 2018; Chang et al., 2017) and corrected lysosomal
deficits and reversed behavioral deficits in a mouse model of FTD
(Arrant et al., 2017). Thus, reduced levels of PGRN that may occur in
FTD and AD may impair protein clearance, causing a build-up in CNS of
p-tau and TDP43, that are linked to neurodegeneration. This suggests
that approaches to increase PGRN levels in brain to compensate for
insufficiency could be therapeutically relevant in diminishing neuro-
degeneration in FTD and possibly AD.
However, PGRN is a protein that is unlikely to effectively cross the
blood brain barrier to enter the brain, limiting its therapeutic use.
Approaches to identify genetic modifiers of PGRN levels, that either
increase GRN transcription, translation or processing, could provide a
unique strategy to develop small molecule drugs that could increase
PGRN levels in brain to treat FTD and AD. This review focuses on
mechanisms that regulate PGRN levels in different brain cells, how
PGRN regulates the clearance of disease-causing proteins from neurons
to impact neurodegeneration and the identification of potential genetic
modifiers of PGRN levels that could be translated into the development
of novel small molecule regulators of PGRN levels to treat FTD and
possibly other neurodegenerative diseases.
2. Cell type selective deficits of PGRN in FTD and disease
PGRN may exert different cell type-specific roles in FTD. For ex-
ample, selective knockout of Grn in neurons in mice can induce changes
in social dominance, a behavioral phenotype of FTD patients (Arrant
et al., 2017). In contrast, selective knockout of Grn in microglia in-
creases self-grooming, an OCD-like behavior in mice, and FTD patients
with GRN mutations exhibit a similar behavior (Krabbe et al., 2017).
The social dominance behavior deficits present in mice with selective
neuronal Grn knockout were not observed in mice with depleted PGRN
in microglia suggesting the behavioral abnormalities may have a cell
autonomous basis.
Complete knockout of Grn in mice that induces OCD-like behavior
can induce neuronal hyperactivity both in neurons in the nucleus ac-
cumbens (Krabbe et al., 2017), an area implicated in development of
OCD and in thalamocortical neurons (Lui et al., 2016). In Grn−/− mice,
pathology, including microgliosis, astrogliosis and deposits of lipofuscin
first occur in the thalamus before spreading to other regions of the brain
(Wils et al., 2012; Yin et al., 2010a; Petkau et al., 2012, 2016; Ahmed
et al., 2010; Ghoshal et al., 2012). The hyperexcitability in the thala-
mocortical neurons was associated with an increase in synaptic pruning
that has been shown to produce a neurodegenerative phenotype in
which inhibitory synapses in the ventral thalamus were eliminated (Lui
et al., 2016). The hyperexcitability resulting from Grn knockout was
related to microglia activation and an increase in innate immunity gene
expression in microglia. Blocking complement production or reducing
TNFα expression, a proinflammatory cytokine, abolished excessive self-
grooming and the associated hyperexcitability in Grn−/− knockout
mice suggesting that PGRN in microglia normally suppresses microglial
activation while loss of PGRN results in excessive microglial activation
and neuronal hyperactivity which may be linked to neurodegeneration
in FTD (Krabbe et al., 2017; Lui et al., 2016).
A number of studies have suggested neuronal hyperactivity may
play a key role in neurodegeneration in FTD and AD (Vossel et al.,
2013). Patients with mild cognitive impairment in the early stages of
AD display hippocampal hyperactivity and epileptiform activity years
before overt cognitive impairment or neuronal loss is detected (Vossel
et al., 2013). Murine models of AD also show epileptic activity leading
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to learning and memory loss prior to overt pathology (Sanchez et al.,
2012). Furthermore, human iPSC-derived neurons from patients with
FTD show hyperactivity that precedes neuronal death (Imamura et al.,
2016). The potential role of early hyperactivity in neurodegeneration
and disease progression is the reason why anti-epileptic agents are
being tested for efficacy in patients with mild cognitive impairment
(Sanchez et al., 2012).
While PGRN in neurons and microglia may contribute to different
aspects of FTD, the role of neuronal and microglial PGRN in disease
pathology is still unclear. Selective deletion of PGRN in either neurons
or microglia produces little of the neuropathology seen in null Grn−/−
mice (Arrant et al., 2017; Petkau et al., 2017a, 2017b). Furthermore,
patients with GRN mutations show heterogenous loss of PGRN in brain,
with levels of the protein decreased in unaffected brain regions, such as
cerebellum and occipital cortex, while PGRN levels appear normal in
brain regions showing neuronal loss, such as the frontal and temporal
cortices (Chen-Plotkin et al., 2010). This may be due to microglia in-
filtration to those regions of the FTD brain most affected by disease
suggesting that the PGRN in the infiltrating microglia may compensate
for the loss of PGRN caused by neuronal death. Interestingly, Arrant
et al. (2018) reported that expression of PGRN in the brains of Grn−/−
mice using an AAV delivery system reduced microgliosis and microglial
activation and the PGRN was mainly delivered to neurons (Arrant et al.,
2018). This suggests that PGRN secreted by neurons may keep micro-
glia in check to reduce neurodegeneration and approaches to increase
PGRN expression in neurons may be potentially useful in treating FTD.
A better understanding of the mechanisms that control PGRN levels
may be useful in developing such therapeutic approaches.
3. Regulation of PGRN levels
3.1. Regulation of PGRN uptake into cells
PGRN is a secreted protein and extracellular PGRN is neuroprotec-
tive (Elia et al., 2019). Multiple mechanisms can control the levels of
extracellular PGRN including its uptake, degradation and secretion that
can impact its protective function.
Despite being a protein, PGRN can be taken up into cells via an
active process involving the neuronal cell membrane receptor sortilin.
Sortilin is a lysosomal sorting receptor that traffics proteases to the
lysosome (Canuel et al., 2008). It also regulates the uptake of extra-
cellular PGRN and delivers it to lysosomes (Hu et al., 2010; Zheng et al.,
2011). Reducing sortilin levels in neurons increases levels of extra-
cellular PGRN and we showed that knocking down sortilin expression in
the neuron-like Neuro2a (N2a) cells resulted in increased extracellular
PGRN (Elia et al., 2019). Importantly, polymorphisms in the sortilin
gene (SORT1) increase the risk of FTD (Philtjens et al., 2018) and
polymorphisms near SORT1 in FTD patients have been shown to in-
crease SORT1 gene expression and reduce extracellular levels of PGRN
(Carrasquillo et al., 2010) suggesting that altered uptake of PGRN may
be linked to FTD.
Prosaposin (PSAP) is a precursor of lysosomal saposin peptides,
which are activators of lysosomal sphingolipid metabolizing enzymes,
and recent work has shown that PSAP, via mannose-6-phosphate re-
ceptor (M6PR) and low density lipoprotein receptor-related protein 1
(LRP1), can facilitate the lysosomal trafficking of PGRN in both the
biosynthetic and endocytic pathways (Zhou et al., 2015). PGRN directly
interacts with PSAP via the granulin D and E motifs and the linker re-
gion between saposin B and C, and itself reciprocally facilitates PSAP
trafficking to lysosomes (Zhou et al., 2017a, 2017b). Interestingly, a
genome-wide association study (GWAS) to find novel regulators of
PGRN levels identified the PSAP locus as significantly associated with
plasma PGRN levels in humans (Nicholson et al., 2016).
3.2. PGRN and lysosomal function
Once it is taken inside cells, PGRN localizes to lysosomes and can
play a direct role in the function of these organelles (Beel et al., 2017;
Chang et al., 2017; Evers et al., 2017; Liu et al., 2015; Tanaka et al.,
2013a, 2013b, 2014, 2017). Tanaka et al. (2017) suggested that PGRN
regulates lysosome acidification and PGRN may directly bind to and
modulate lysosomal enzymes, such as cathepsin D (Beel et al., 2017).
Furthermore, lysosome activity regulates PGRN levels since inhibition
of lysosome function with bafilomycin A1 increased PGRN levels in
neuronal cells (Capell et al., 2011, 2014). This suggests that PGRN may
have a reciprocal relationship with lysosomes: it can affect lysosome
activity and, in turn, lysosomes can regulate PGRN levels by degrading
the protein.
The relationship between PGRN and lysosomal function may have
relevance in FTD since the neuropathology of FTD has been linked to
lysosomal dysfunction (Ward et al., 2017). Increased lipofuscinosis,
indicative of lysosome dysfunction, and other lysosomal abnormalities
were found in postmortem cortex of FTD patients with heterozygous
GRN mutations. In FTD patients, noninvasive retinal imaging revealed
preclinical retinal lipofuscinosis in heterozygous GRN mutation carriers
(Ward et al., 2017). Lymphoblasts from heterozygous GRN mutation
carriers also accumulated prominent amounts of lipofuscin, which
could be rescued by normalizing PGRN expression (Ward et al., 2017).
Fibroblasts from heterozygous GRN mutation carriers also showed im-
paired lysosomal protease activity suggesting that FTD may be due to
PGRN insufficiency associated with lysosomal dysfunction.
Mouse models of FTD (Grn ± mice) also show lysosomal dysfunc-
tion in brain (Ahmed et al., 2010; Arrant et al., 2017, 2018). In fact,
increasing brain PGRN levels in vivo in Grn ± mice reversed the lyso-
somal neuropathology and social behavior deficits (Arrant et al., 2017b,
2018). We showed that reducing PGRN levels in mouse cortical neurons
either by knockdown using Grn siRNA or in neurons from PGRN-defi-
cient (GrnR493X/+) mice, resulted in an increase in the size and number
of lysosomes, which usually indicates dysfunction (Elia et al., 2019).
Furthermore, PGRN-deficient lysosomes imaged by electron microscopy
appear overloaded with aggregated undigested material suggesting
impaired function, and iPSC-derived human cortical neurons from FTD
patients harboring the GRN493X/+ mutation also display enlarged ly-
sosomes (unpublished results).
PGRN deficiency also leads to lysosome dysfunction in microglia,
with both cell autonomous and nonautonomous consequences (Gotzl
et al., 2018, 2019; Lui et al., 2016; Tanaka, 2017). Götzl et al. (2018)
showed that loss of PGRN led to altered lysosome cathepsin levels and
maturation in microglia which impaired lysosome function in that cell
type but triggered enhanced lysosomal cathepsin maturation in other
brain cell types (Gotzl et al., 2018). In addition, Götzl et al. (2019)
showed that PGRN deficiency in microglia caused these cells to adopt a
neurodegenerative disease-associated activation state compared to
triggering receptor expressed on myeloid cells 2 (TREM2)-deficient
microglia which adopted a homeostatic activation state, with the PGRN
deficient microglia displaying altered phagocytosis, migration, and
clustering around amyloid plaques (Gotzl et al., 2019). Finally, Lui
et al., 2016 showed that PGRN deficiency led to lysosome defects and
altered microglial complement production and activation that led to
aberrant synaptic pruning in neurons and induced OCD behavior in
mice (Lui et al., 2016). These findings indicate that a common neuro-
pathological defect resulting from loss of PGRN in FTD patients and in
FTD models is lysosomal dysfunction, with different functional con-
sequences occurring in microglia vs. neurons.
3.3. PGRN and autophagy
In addition to directly regulating lysosomal function, PGRN may
also have a role in modulating autophagy, the main neuronal pathway
involved in clearance of misfolded, disease causing proteins such as p-
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tau and TDP43. PGRN has been shown to inhibit autophagy (Chang
et al., 2017), and the addition of extracellular PGRN to neurons re-
pressed autophagy. In contrast, inhibiting Grn expression with siRNA
caused an exaggerated increase in autophagy in hepatocytes (Liu et al.,
2015).
To test if PGRN directly modulates autophagy in neurons, we em-
ployed a novel, cell imaging technology, optical pulse-labelling (OPL)
to measure autophagic flux in single primary mouse cortical neurons
using robotic microscopy and longitudinal imaging of a photoswitch-
able fluorescent protein reporter, EOS2-LC362. Using this approach, we
found that knockdown of PGRN levels by>50% resulted in an upre-
gulation of autophagic flux in mouse cortical neurons (Elia et al., 2019).
We and others (Osaka et al., 2015) showed that pharmacological in-
hibition of autophagy with 3-methyladenine (3-MA) increased levels of
extracellular PGRN, whereas overexpressing a genetic inducer of au-
tophagy, Beclin1, decreased PGRN secretion. Thus, there appears to be
a reciprocal relationship between PGRN and autophagy, with PGRN
inhibiting autophagic flux and autophagy reducing excess secretion of
PGRN from neurons.
Downregulating autophagy is counterintuitive to studies showing a
beneficial role for autophagy in neurodegenerative diseases. However,
excessive autophagy can lead to activation of alternative cell death
pathways as seen in cerebral ischemia (Shi et al., 2012; Bialik et al.,
2018; Jaeger and Wyss-Coray, 2009). Autophagic stress could also arise
from inefficient autophagosome turnover due to lysosomal defects. Lee
and Gao (2009) have shown that excess accumulation of autophago-
somes due to dysfunction of the endosomal sorting complex required
for transport III (ESCRT-III) contributed to neuronal cell loss in a me-
chanism that was uncoupled from the accumulation of ubiquitinated
protein aggregates (Lee and Gao, 2009). Inhibiting autophagy by
treatment with 3-MA or knocking-out atg5 delayed this neuronal cell
loss without affecting the endosomal accumulation of ubiquitinated
proteins caused by the ESCRT-III dysfunction, suggesting that dysre-
gulated autophagy can be a co-contributor to neurodegeneration in
addition to the aberrant accumulation of toxic proteins (Lee and Gao,
2009).
Autophagy and lysosomal activity are linked in neurons since au-
tophagy is responsible to transporting cargoes destined to degradation
to lysosomes. The enhanced autophagy caused by PGRN insufficiency
may also be linked to a progressive impairment of lysosome function
because in essence, the lysosomes are overworked (Elrick and
Lieberman, 2013; Elrick et al., 2012). If PGRN deficiency results in an
impaired autophagy-lysosomal pathway (ALP) in neurons, then this
may explain why in PGRN deficient neurons there is increased ex-
pression of aggregated cytoplasmic TDP43 which is normally cleared by
the ALP.
3.4. PGRN and TDP43 pathology
Insufficiency of PGRN in brain results in the accumulation and ag-
gregation of TDP43 in the cytoplasm of neurons and reduced transport
of TDP43 to the nucleus, impairing its normal regulation of RNA.
Inability of TDP43 to shuttle from the cytoplasm to the nucleus is a
critical pathogenic mechanism in ALS and likely in FTD (Ayala et al.,
2008; Neumann et al., 2006; Ward et al., 2014). We showed that cor-
tical neurons from transgenic Grn493X/+ mice with PGRN hap-
loinsufficiency exhibit TDP43 pathology; they express significant toxic
cytoplasmic accumulation of TDP4362. We also found that Grn knock-
down reduced the turnover of TDP43 in individual neurons nearly
three-fold, monitored with OPL technology. This finding suggests that
reduced turnover and increased accumulation and aggregation of cy-
toplasmic TDP43 in PGRN-deficient neurons may be caused by im-
paired clearance of TDP43 by the ALP. Furthermore, we found that
cortical neurons overexpressing TDP43 have a significantly increased
risk of death. Adding exogenous PGRN to these neurons reduced TDP43
cytoplasmic levels and increased neuronal survival. These findings are
consistent with PGRN restoring ALP functions to clear toxic forms of
TDP43 to reduce neurodegeneration, since we know that TDP43 can be
cleared via the ALP. As FTD and AD are associated with diminished
levels of brain PGRN and TDP43 pathology, our findings suggest that
PGRN replacement therapy may have disease-modifying con-
sequences to treat FTD and AD.
4. Genetic regulators of neuronal PGRN expression
To better define the neuronal mechanisms that control PGRN ex-
pression and to identify potential novel molecular targets to develop
drugs to increase PGRN expression to treat FTD, we employed an un-
biased whole-genome RNAi screen on N2a cells, which endogenously
express PGRN, to identify genes that control the extracellular levels of
PGRN (Elia et al., 2019). The screen identified a select group of genes
that have known roles in regulating ALP. The targets are druggable
since small molecule inhibitors have been developed against the pro-
teins encoded by these genes. Furthermore, reduction in expression of
these potential genetic modifiers of PGRN levels increased expression
and secretion of PGRN from N2a cells and mouse primary cortical
neurons. It also raised PGRN levels in mouse Grn ± haploinsufficient
cortical neurons to levels found in wild-type neurons. This suggests that
drugs targeting these gene products might be able to reverse PGRN
insufficiency in humans such as FTD patients.
The cassette of potential genetic modifiers of PGRN levels included
(Gabarap1, Tom1, Tsg101, Foxo1, Sort1, Jmjd6, Elk3, and Trap1/
HSP90L). GABARAP1 is a member of the LC3 family of proteins that are
essential for autophagy flux and mediate autophagosome formation and
maturation and are also important in autophagosome-to-lysosome fu-
sion (Albanesi et al., 2015; Jenzer et al., 2014; Martens, 2016; McEwan
et al., 2015; Nguyen et al., 2016; Wang et al., 2015). TOM1 is an en-
dosome protein that functions in autophagosome-to-lysosome fusion
(Bond et al., 2011; Tumbarello et al., 2012, 2013; Wang et al., 2010).
TSG101 is an ESCRT1 protein that is required for endosomal matura-
tion, trafficking and exosome secretion (Babst et al., 2000; Colombo
et al., 2013). FOXO1 is a forkhead O family transcription factor that has
been shown to regulate autophagy in response to stress (He et al., 2018;
Zhao et al., 2010). JMJD6 encodes a jumonji C-domain containing,
bifunctional arginine demethylase and lysyl-hydroxylase (Chang et al.,
2007; Webby et al., 2009; Boeckel et al., 2011; Heim et al., 2014;
Mantri et al., 2011; Poulard et al., 2014; Unoki et al., 2013; Walport
et al., 2016; Zhang et al., 2015) that has been shown to promote au-
tophagy in triple negative breast cancer cells (Liu et al., 2018). Elk3 is
an ETS transcription factor that functions as a transcriptional repressor
and regulates gene expression during angiogenesis and hypoxia (Gross
et al., 2007, 2008; Heo and Cho, 2014). Knockdown of ELK3 in a triple
negative breast cancer cell line led to a repression of autophagy via
activation of the PI3K/Akt/mTOR pathway and, as a result, conferred
sensitivity to the anticancer drug, doxorubicin (Park et al., 2016).
TRAP1/HSP90L is a mitochondrial chaperone protein and a member of
the HSP90 family of heat shock proteins (Altieri et al., 2012; Amoroso
et al., 2012; Baldo et al., 2012; Hong et al., 2013; Matassa et al., 2012;
Putcha et al., 2010; Takemoto et al., 2011). TRAP1/HSP90L has been
shown recently to act as a regulator of autophagy in lung cancer cells
(Barbosa et al., 2018).
To determine if the potential genetic modifiers may act via a
common mechanism to increase PGRN levels, we tested if reducing
expression of these genes affected transcriptional activity of Grn in N2a
cells. siRNA knockdown of Jmjd6 or Foxo1 increased the relative
abundance of Grn mRNA and PGRN levels. In contrast, siRNA knock-
down of Trap1/Hsp90L, Tom1, or Tsg101 did not affect Grn mRNA,
despite increasing extracellular PGRN levels. Thus, these validated
genes parse into two distinct mechanistic categories: those that regulate
PGRN levels primarily at the transcriptional level (Jmjd6; Foxo1) and
those that regulate PGRN levels primarily at a post-translational level
(Trap1/Hsp90L; Tom1; Tsg101), suggesting that PGRN levels are
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regulated by multiple mechanisms.
5. Small molecule enhancers of PGRN expression as potential
drugs to treat FTD
Since PGRN deficiency is a potential disease mechanism in a sig-
nificant population of FTD patients, then identifying drugs that safely
increase PGRN levels in brain could be potentially developed as ther-
apeutics to treat FTD. We found two genes, Foxo1, and Trap1/Hsp90L
that are potentially interesting molecular targets to develop small mo-
lecule drugs to treat FTD since inhibiting the activity of their gene
products resulted in an increase PGRN levels in neurons.
5.1. Foxo1 inhibitors
Small molecule drugs inhibitors, PsammaplyseneA (PSA)
(Mojsilovic-Petrovic et al., 2009) and AS1842856126 have been devel-
oped targeting Foxo1 gene product and we tested those drugs for effi-
cacy in increasing PGRN levels in neurons. We were interested in Foxo1
as a potential genetic modifier because reducing its expression resulted
in increased levels of Grn mRNA, suggesting that small molecule in-
hibitors might produce a long-lasting increase in PGRN levels in brain
neurons. Furthermore, knocking down expression of Foxo1 in PGRN-
deficient neurons not only increased PGRN levels but also suppressed
the lysosome enlargement suggesting that Foxo1 inhibitors might re-
verse the neuropathology caused by PGRN insufficiency.
Both PSA and AS1842856, which act through different mechanisms
to block Foxo1 activity, effectively and potently increased PGRN levels
in N2A cells in a dose dependent manner. PSA produced a 2.5-fold
increase in PGRN at concentrations as low at 10 nM AS1842856 at
10 nM increased PGRN levels by 50%, which would be sufficient to
reverse PGRN haploinsufficiency. Both inhibitors showed a sustained
increase in PGRN levels.
The efficacy of these two drugs to increase PGRN level is of potential
therapeutic utility. PSA reduces neurodegeneration in models of ALS
(Mojsilovic-Petrovic et al., 2009), which, like FTD, exhibit significant
TDP43 pathology, suggesting that Foxo1 inhibitors may be neuropro-
tective. AS1842856 is orally bioavailable and has been used to in-
vestigate the in vivo role of Foxo1 in diabetes (Nagashima et al., 2010).
Both compounds have been tested in animals and produce no overt side
effects. If these drugs are effective in in vivo animal models of FTD and
in vitro human models of FTD (iPSC derived neurons from FTD patients)
then Foxo1 may be a unique target for developing drugs to treat FTD.
5.2. TRAP1 inhibitors
TRAP1 is of interest because it mediates the functions of the
proinflammatory cytokine TNFα (Altieri et al., 2012; Matassa et al.,
2012), and prior evidence had already suggested an important role of
TNFα in causing neurodegeneration in FTD. Thus, TRAP1 inhibition
might be effective in blocking neurodegeneration in FTD through at
least two mechanisms: by reducing the degenerative effects of TNFα
and by reversing PGRN haploinsufficiency to return PGRN to normal
levels. In fact, there is an interesting relationship between PGRN and
TNFα since PGRN has been reported to inhibit downstream activity of
TNFα by reducing expression of the TNFα-regulated cytokines CXCL9,
CXCL10 and IL-10 (Mundra et al., 2016; Wei et al., 2014). Thus, by
increasing PGRN levels, TRAP1 inhibitors may further block the
proinflammatory actions of TNFα.
TRAP1 is a member of the HSP90 family and HSP90 inhibitors block
TRAP1 function (Baldo et al., 2012; Hong et al., 2013; Matassa et al.,
2012). We tested two HSP90 inhibitors, 17AAG and AUY922, for their
ability to increase PGRN levels in N2a cells (Elia et al., 2019; Hong
et al., 2013). We tested these compounds because they effectively in-
hibit TRAP1 and have also undergone multiple Phase 1 and 2 clinical
trials as anticancer agents (Banerji et al., 2005; Goetz et al., 2005; Grem
et al., 2005; Heath et al., 2008; Nowakowski et al., 2006; Ramanathan
et al., 2005, 2007; Ronnen et al., 2006; Solit et al., 2007, 2008; Kong
et al., 2016), are well tolerated in humans, and produce no obvious
limiting side effects even with chronic administration. Because the
TRAP1 inhibitors are safe in humans, if they are found effective in
preclinical models of FTD, they could eventually be transitioned for
testing in humans to treat FTD. Both showed dose-dependent increases
in PGRN (Elia et al., 2019). AUY922 increased PGRN levels by threefold
at concentrations as low as 100 nM. Importantly, we also tested a third
TRAP1 inhibitor, NVP-HSP990. NVP-HSP990 is being developed to
treat cancer and has been shown to have good pharmacokinetics and
pharmacodynamic properties after oral administration and has been
shown to be safe in Phase 1 clinical trials (McBride et al., 2014;
Spreafico et al., 2015). When administered intraperitonially at a single
dose (12 mg/kg) to either wild-type mice or an animal model of FTD
with PGRN haploinsufficiency (Grn R493X/+) it significantly increased
PGRN levels in brain by more than 50% indicating it can reverse PGRN
haploinsufficiency in vivo (unpublished results). We also showed target
engagement of NVP-HSP990 in vivo in brain by measuring changes in
ATPase activity (unpublished results). NVP-HSP990 has been reported
to be a more potent inhibitor of TRAP1 ATPase activity than 17-AAG
(Menezes et al., 2012). At the dose of NVP-HSP990 that increases PGRN
levels in brain by at least 50%, the drug blocks TRAP1 ATPase activity
by a similar amount indicating the drug increases PGRN levels by
blocking TRAP1 activity in brain. This finding is important because it
shows for the first time that a TRAP1 inhibitor that gets into the brain
after peripheral administration increases PGRN in brain, which we can
now use to test for preclinical efficacy in FTD animal models and pos-
sibly transition to development as a treatment of FTD.
5.3. Therapeutic considerations of small molecule PGRN inducers
While drug inhibitors targeting genetic modifiers of PGRN expres-
sion including Gabarap1, Foxo1 Tom1, Tsg101, TRAP1, Jmjd6, and
Elk3 may have utility in treating FTD, caution may be necessary in their
long term use because they may be expected to produce off-target ac-
tions, such as reducing autophagy, increasing their potential for indu-
cing side effects. Little is known with regards to the role of each of these
molecular targets in the control of autophagy in brain neurons. It is not
known whether partial inhibition of individual targets may be com-
pensated for and have minor overall effects on autophagy and protein
clearance. In fact, there are few small molecule drugs that selectively
inhibit specific proteins in the autophagy pathway, and those that in-
hibit TRAP1 and Foxo1, as described above, produce no overt side ef-
fects in animals or humans.
However, a more important question is how a drug that inhibits
autophagy could be useful in treating a disease like FTD that is asso-
ciated with increased levels of a toxic misfolded protein such as TDP43
which may build up in neurons in part because it is not effectively
cleared from brain cells through the autophagic-lysosomal pathway.
While a definitive answer to this question is not available, it is possible
that the ameliorative effects of small molecule drug inhibitors of TRAP1
and Foxo1 may be due to their multiple mechanisms of actions as is the
case for most drugs that treat brain disorders. For example, the ability
of Foxo1 inhibitors to increase PGRN levels is due at least in part to
their ability to increase PGRN mRNA levels which is not likely to be due
to inhibiting autophagy. Also, TRAP1 inhibitors, as described above not
only affect autophagy but also may reducee the degenerative effects of
the proinflammatory cytokine TNFα. Thus, the potential therapeutic
effects of TRAP1 and Foxo1 inhibitors may be primarily due to their
ability to reverse the loss of PGRN in disease. The effects of these drugs
on autophagy may have minor consequences in their overall ther-
apeutic benefits in treating brain diseases.
L.P. Elia, et al. Neuropharmacology 166 (2020) 107948
5
6. Summary and future directions
GRN-linked FTD is a multifaceted disease with specific neuronal
pathologies and neuroinflammation resulting from reduced PGRN le-
vels in the brain. Understanding how low PGRN levels lead to neuro-
degeneration has been a central and important focus of current research
to identify targets to treat this incurable and progressively fatal disease.
This review has focused on the identification of novel genetic and
chemical modulators that act through multiple mechanisms to restore
neuronal PGRN to control levels in the brain, and reverse functional
deficits in the ALP.
The complexity of FTD poses a unique challenge for drug develop-
ment and so the identification of multiple strategies to increase PGRN
levels will help to ensure a high likelihood of success to develop ef-
fective therapeutics. While this review has focused on a strategy to raise
PGRN levels in the brain, additional strategies directly targeting neu-
roinflammation or TDP43 pathology can be envisioned. Directly tar-
geting the neuroinflammation associated with reduced PGRN levels,
might include identifying ways to dampen disease associated microglial
inflammation or to mitigate the neurotoxic effects of proinflammatory
cytokines. Directly targeting the toxic aggregation and/or mislocaliza-
tion of TDP43 might include identifying ways to modulate autophagy
and/or enhance lysosome function to help promote the efficient clear-
ance of TDP-43 aggregates.
FTD is a rare disease and qualifies as an orphan indication. This
opens up a number of grant and accelerated approval mechanisms
through the Orphan Drug Act and FDA Office of Orphan Products
Developments. There is broader potential for treating other neurode-
generative diseases, as a successful FTD drug that is rapidly approved
will have been clinically validated. This can help offset or lower the
potential financial risks for therapeutics development for AD, for in-
stance, for which reduced PGRN levels have been identified as a known
risk factor for this disease. However, there is a need to develop more
rigorous preclinical models that faithfully and effectively recapitulate
the human disease to ensure success in clinical trials and in translating
potential drugs into approved treatments. New protocols to successfully
differentiate human induced pluripotent stem cells (iPSC) into specific
neuronal subtypes, microglia, or astrocytes are now available, opening
up the potential of developing more effective human preclinical cell
models. The ability to differentiate the key cell types affected in FTD
will enable a better understanding of cell type specific autonomous as
well as nonautonomous phenotypes. These cell models can complement
the FTD animal models, which fail to recapitulate some of the key
pathologies of the human disease, such as excessive neuroinflamma-
tion. Human iPSC-derived cell models may represent new potential to
develop better in vivo animal models for FTD: a very recent publication
from Hasselmann et al. (2019), showed that it is possible to develop a
chimeric mouse using xenotransplantation of human iPSC-derived mi-
croglia (Hasselmann, 2019). Human iPSC-derived hematopoietic-pro-
genitors transplanted into the postnatal brain of humanized, immune-
compromised mice led to differentiation into microglia that can re-
spond to inflammatory challenges and AD pathology (Hasselmann,
2019). This could enable the development of more rigorous FTD animal
models that recapitulate the inflammatory pathology currently lacking
from the existing models. Given the current advances in CRISPR tech-
nology, there is an exciting potential for new screening opportunities in
human iPSC-derived FTD microglia that can be performed and func-
tionally validated in vivo in chimeric animals, thus providing powerful
new approaches to expedite drug development for FTD and AD.
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